CareDx, Inc 8-K

Summary

Q2 2026 results and raised FY2026 guidance. Revenue grew 52% Y/Y, driven by continued adoption of molecular testing across transplant programs, higher testing activity in surveillance and for-cause settings, favorable reimbursement, and expansion of Patient and Digital Solutions. An updated corporate presentation, current as of 6/30/2026, was also posted.

FY2026 revenue guidance was raised to $490M-$500M from $447M-$465M, and adjusted EBITDA guidance was raised to $66M-$78M from $43M-$57M.

Key Figures

• Testing Services revenue was $100M, +61% Y/Y, on approximately 58,000 tests, +17% Y/Y; excluding $16M of revenue recognized for tests performed in prior periods, Testing Services revenue grew approximately 28% Y/Y. Average revenue per test was approximately $1,720, including that prior-period revenue.
• Patient and Digital Solutions revenue was $19M, +50% Y/Y; Lab Product revenue was $13M, +8% Y/Y. The Lab Products business was sold to Eurobio Scientific, with the sale closing on 6/30/2026 and producing a $113M gain included in GAAP operating income but excluded from non-GAAP operating income; future periods will no longer include Lab Products results. Cash and cash equivalents were $374M at quarter-end, vs $65.4M at 12/31/2025.
• CMS finalized Medicare coverage policy for AlloSure and AlloMap transplant tests. CareDx also reported new clinical evidence for NavDx, a test used to inform patient management, and AlloSure, and continued work toward CLIA readiness for AlloHeme, its cell therapy pipeline program.

Guidance

Guidance changes, derived from earlier filings

Metric	Period	Earlier guidance	Guidance now	Change
Revenue	FY2026	$447M-$465M	$490M-$500M	raised
Adjusted EBITDA (non-GAAP)	FY2026	$43M-$57M	$66M-$78M	raised

Investor Takeaways

• Track Testing Services volume and revenue excluding prior-period testing: continued growth would support the company’s view that transplant-program adoption and testing activity are driving the business.
• Watch integration of Naveris and progress toward the cell therapy launch and AlloHeme CLIA readiness for evidence of execution in specialty oncology and cell therapy.